Overview
The value of 4D body-to-whole dynamic acquisition in FDG PET / CT to differentiate progression / pseudo-progression during the first therapeutic assessment (PET1) of metastatic melanoma treated with immune checkpoint inhibitors (ICI)to predict the progression of the disease..
Eligibility
Inclusion Criteria:
- Patient old ≥ 18 years
- With metastatic melanoma
- Treated with anti-PD1 : Nivolumab or Pembrolizumab or Combo IPI-Nivo
- Having formulated a non-opposition
Exclusion Criteria:
- - Minor patient < 18 years
- Pregnancy or breastfeeding
- Other type of tumor than metastatic melanoma
- Non-eligibility for the examination
- Refusal of participation